Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated

Bone Marrow Transplantation

Volumn 46, Issue 2, 2011, Pages 300-307

  Poutsiaka, D D ^a   Munson, D ^b   Price, L L ^a   Chan, G W ^a   Snydman, D R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute GVHD; blood stream infection; hematopoietic SCT; mortality; multivariable model

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; ANTHRACYCLINE; ANTIBODY; ANTINEOPLASTIC ANTIMETABOLITE; COTRIMOXAZOLE; CYCLOSPORIN A; CYTOKINE; ETOPOSIDE; FLUCONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VINCA ALKALOID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INFECTION PREVENTION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SERODIAGNOSIS; STAPHYLOCOCCUS INFECTION; TIME OF DEATH;

ACUTE DISEASE; ADULT; BACTEREMIA; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 79951681800     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.112     Document Type: Article

References (50)

1. Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 2007; 40: 63-70. (Pubitemid 47018415)
2. Copelan EA. Hematopoietic stem-cell transplantation. [see comment]. New Engl J Med 2006; 354: 1813-1826.
3. Duran-Struuck R, Reddy P. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2008; 85: 303-308. (Pubitemid 351322750)
4. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
5. Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 2004; 33: 881-889. (Pubitemid 38660120)
6. Horan T, Gaynes R. Surveillance of nosocomial infections. In: Hospital Epidemiology and Infection Control, 3rd edn. Lippincott, Williams & Wilkeins: Philadelphia, 2004, pp 1659-1702.
7. DesJardin JA, Falagas ME, Ruthazer R, Griffith J, Wawrose D, Schenkein D et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med 1999; 131: 641-647. (Pubitemid 29517948)
8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events. National Cancer Institute: Bethesda, MD, USA, 2006, http://ctep.cancer. gov.
10. Flowers ME, Traina F, Storer B, Maris M, Bethge WA, Carpenter P et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant 2005; 35: 277-282. (Pubitemid 40268300)
11. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755. (Pubitemid 44061380)
12. Bergstralh E, Therneau T. %Schoen.sas. Mayo Foundations for Medical Education and Research: Rochester, MN, USA, 2002, Copyright 2006.
13. Harrell JFE. %daspline.sas.Mayo Foundations for Medical Education and Research: Rochester, MN, USA, 1991, Copyright 2006.
14. Allison PD. Survival Analysis Using SAS(TM): A Practical GuideEstimating Cox regression models with PROC PHREG. SAS Institute, Inc.: Cary, NC, 1995.
15. Wolkewitz M, Vonberg RP, Grundmann H, Beyersmann J, Gastmeier P, Barwolff S et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. [see comment]. Critical Care (London, England) 2008; 12: R44.
16. Neher A, Arnitz R, Gstottner M, Schafer D, Kross EM, Nagl M et al. Antimicrobial activity of dexamethasone and its combination with N-chlorotaurine. Arch Otolaryngol Head Neck Surg 2008; 134: 615-620. (Pubitemid 351871021)
17. Unsal H, Balkaya M, Unsal C, Biyik H, Basbulbul G, Poyrazoglu E et al. The short-term effects of different doses of dexamethasone on the numbers of some bacteria in the ileum. Dig DisSc 2008; 53: 1842-1845.
18. van Vliet MJ, Tissing WJ, Dun CA, Meessen NE, Kamps WA, de Bont ES et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 2009; 49: 262-270.
19. Johansson JE, Ekman T, Johansson J-E, Ekman T. Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients. Dig Dis Sci 2007; 52: 2340-2345. (Pubitemid 47246497)
20. Bostrom L, Ringden O, Sundberg B, Linde A, Tollemar J, Nilsson B. Pretransplant herpesvirus serology and acute graftversus-host disease. Transplantation 1988; 46: 548-552.
21. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245. (Pubitemid 30167720)
22. Meijer E, Dekker AW, Rozenberg-Arska M, Weersink AJ, Verdonck LF. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis 2002; 35: 703-712. (Pubitemid 35024731)
23. Remberger M, Aschan J, Lonnqvist B, Carlens S, Gustafsson B, Hentschke P et al. An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. Eur J Haematol 2001; 66: 50-56. (Pubitemid 32099410)
24. Gratama JW, Zwaan FE, Stijnen T, Weijers TF, Weiland HT, D'Amaro J et al. Herpes-virus immunity and acute graftversus-host disease. Lancet 1987; 1: 471-474. (Pubitemid 17036513)
25. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-4260. (Pubitemid 37494081)
26. Appleton AL, Sviland L, Peiris JS, Taylor CE, Wilkes J, Green MA et al. Role of target organ infection with cytomegalovirus in the pathogenesis of graft-versus-host disease. Bone Marrow Transplant 1995; 15: 557-561.
27. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373-380. (Pubitemid 20239951)
28. Miller W, Flynn P, McCullough J, Balfour Jr HH, Goldman A, Haake R et a.l Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162-1167. (Pubitemid 16116435)
29. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, Nakagawa M, Kandabashi K, Izutsu K et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 813-819. (Pubitemid 41613305)
30. Daly A, McAfee S, Dey B, Colby C, Schulte L, Yeap B et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003; 9: 373-382. (Pubitemid 38351808)
31. Frere P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E et al. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplant 2006; 37: 411-418. (Pubitemid 43250476)
32. Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation 2002; 74: 49-54. (Pubitemid 34779210)
33. Matsumura T, Narimatsu H, Kami M, Yuji K, Kusumi E, Hori A et al. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients. Biol Blood Marrow Transplant 2007; 13: 577-583. (Pubitemid 46585928)
34. Meyers J, Flournoy N, Thomas E. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488. (Pubitemid 16135651)
35. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLAidentical sibling transplantation with antithymocyte globulinbased reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177. (Pubitemid 37428382)
36. Reddy V, Meier-Kriesche HU, Greene S, Schold JD, Wingard JR. Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 698-705. (Pubitemid 41194978)
37. van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1487-1498. (Pubitemid 350091387)
38. Mocarski Jr ES. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002; 10: 332-339. (Pubitemid 34756533)
39. Mocarski Jr ES. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 2004; 6: 707-717. (Pubitemid 39077378)
40. Peggs KS, Mackinnon S. Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation. Int J Biochem Cell Biol 2004; 36: 695-701. (Pubitemid 38316824)
41. Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328-1332. (Pubitemid 24245903)
42. Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7: 11-17. (Pubitemid 40978668)
43. Cappellano P, Viscoli C, Bruzzi P, Van Lint MT, Pereira CA, Bacigalupo A. Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiologica 2007; 30: 89-99.
44. Ninin E, Milpied N, Moreau P, Andre-Richet B, Morineau N, Mahe B et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33: 41-47. (Pubitemid 32554501)
45. Kruger W, Russmann B, Kroger N, Salomon C, Ekopf N, Elsner HA et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 589-597. (Pubitemid 29137448)
46. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387-394.
47. Sparrelid E, Hagglund H, Remberger M, Ringden O, Lonnqvist B, Ljungman P et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22: 795-800. (Pubitemid 28488324)
48. de Lissovoy G, Hurd D, Carter S, Beatty P, Ewell M, Henslee- Downey J et al. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease. Bone Marrow Transplant 2005; 36: 539-546. (Pubitemid 43118149)
49. Esperou H, Brunot A, Roudot-Thoraval F, Buzyn A, Dhedin N, Rio B et al. Predicting the costs of allogeneic sibling stemcell transplantation: results from a prospective, multicenter, French study. Transplantation 2004; 77: 1854-1858. (Pubitemid 38822208)
50. Moya R, Espigado I, Parody R, Carmona M, Marquez F, De Blas JM. Evaluation of readmissions in hematopoietic stem cell transplant recipients. Transplant Proceedings 2006; 38: 2591-2592. (Pubitemid 44693712)